| Literature DB >> 25406492 |
Jaeyoung Cho, Sung-Jun Ko, Se Joong Kim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Jae Ho Lee, Choon-Taek Lee1.
Abstract
BACKGROUND: Percutaneous needle aspiration or biopsy (PCNA or PCNB) is an established diagnostic technique that has a high diagnostic yield. However, its role in the diagnosis of nodular ground-glass opacities (nGGOs) is controversial, and the necessity of preoperative histologic confirmation by PCNA or PCNB in nGGOs has not been well addressed.Entities:
Mesh:
Year: 2014 PMID: 25406492 PMCID: PMC4247129 DOI: 10.1186/1471-2407-14-838
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Seoul National University Bundang Hospital guidelines for pure GGO (A) and part-solid GGO (B). GGO, ground-glass opacity; LDCT, low-dose computed tomography; HRCT, high resolution computed tomography.
Figure 2Flow chart. Of the 330 resected nGGOs, 314 were diagnosed as lung adenocarcinoma, and the rate of malignancy was 95.2%. aAmong 21 nGGOs, six nGGOs were co-resected with indicated GGO nodules and one nGGO was resected because metastasis of underlying thyroid cancer was strongly suspected. The decision to resect the other 14 GGOs was mainly influenced by the patients’ will. nGGOs, nodular ground-glass opacities; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; ADC, adenocarcinoma; AAH, atypical adenomatous hyperplasia.
Baseline and radiologic characteristics of the study patients (n =330)
| Benign | Malignant |
| |
|---|---|---|---|
| (n =16) | (n =314) | ||
|
| |||
| Age (years)a | 58.1 ± 7.3 | 62.1 ± 10.4 | 0.127 |
| Male sex, no. (%) | 9 (56.3) | 147 (46.8) | 0.461 |
| Smoking, no. (%) | 0.555 | ||
| Never-smoker | 8 (50.0) | 196 (62.4) | |
| Ex-smoker | 6 (37.5) | 95 (30.3) | |
| Current-smoker | 2 (12.5) | 23 (7.3) | |
| Smoking (PY) | 12.2 ± 17.3 | 10.0 ± 16.5 | 0.605 |
|
| |||
| Size (mm)a | 15.1 ± 9.3 | 20.3 ± 11.0 | 0.063 |
| GGO pattern, no. (%) | 1.0 | ||
| Pure | 3 (18.8) | 72 (22.9) | |
| Part-solid | 13 (81.3) | 242 (77.1) | |
| TDR (%)a | 86.6 ± 17.5 | 83.3 ± 20.7 | 0.536 |
| Air bronchogram, no. (%) | 7 (43.8) | 175 (55.7) | 0.347 |
| Bubble lucency, no. (%) | 2 (12.5) | 46 (14.6) | 1.0 |
| Pleural or fissure retraction, no. (%) | 4 (25.0) | 143 (45.5) | 0.107 |
| Irregular margin, no. (%) | 6 (37.5) | 148 (47.1) | 0.451 |
| Maximal SUV on FDG-PET/CTa,b | 0.39 ± 0.67 | 1.19 ± 1.28 | 0.101 |
| Progression, no. (%)c | 1.0 | ||
| Progression | 4/12 (33.3)d | 88/232 (37.9) | |
| Without progression | 8/12 (66.7) | 144/232 (62.1)e |
aExpressed as mean values ± standard deviations.
bAmong the 330 nGGOs, 191 underwent FDG-PET/CT.
cSerial CT scans at least 4 weeks interval were available for 244 nGGOs over the median follow-up duration of 9.1 months (range, 7.3 - 123.9 months).
dThree GGOs had increased in whole GGO size and one pure GGO had become a part solid nodule. The two of three GGOs were subpleural fibrosis and the other one was atypical adenomatous hyperplasia on the final pathology. The one GGO becoming a part solid nodule was the anthracofibrotic nodule.
eOne GGO had decreased in size, which was adenocarcinoma, acinar predominant.
PY, pack-years; GGO, ground-glass opacity; TDR, tumor disappearance rate; SUV, maximal standardized uptake value; FDG-PET/CT, fluorodeoxyglucose-positron emission tomography/computed tomography.
Multivariate analysis for the risk of malignancy according to ground glass opacity size
| Size | Total | Benign | Malignant | p-value | OR | 95% CI |
|---|---|---|---|---|---|---|
| (n =330) | (n =16) | (n =314) | ||||
| < 10 mm | 39 | 5 (31.3) | 34 (10.8) | 0.015 | ||
| 10 mm ≤ <15 mm | 76 | 5 (31.3) | 71 (22.6) | 0.146 | 2.777 | 0.701 – 10.994 |
| 15 mm ≤ | 215 | 6 (37.5) | 209 (66.6) | 0.004 | 8.323 | 1.968 – 35.196 |
OR, odds ratio; CI, confidence interval.
Pathologic diagnoses
|
|
|
|
| Adenocarcinoma in situ | 38 | 12.1 |
| Minimally invasive adenocarcinoma | 63 | 20.1 |
| Invasive adenocarcinoma | ||
| Lepidic predominant | 33 | 10.5 |
| Acinar predominant | 115 | 36.6 |
| Papillary predominant | 52 | 16.6 |
| Micropapillary predominant | 1 | 0.32 |
| Solid predominant | 2 | 0.64 |
| Variants | ||
| Mucinous adenocarcinoma | 9 | 2.9 |
| Enteric | 1 | 0.32 |
|
|
|
|
| Focal interstitial fibrosis | 5 | 31.3 |
| Atypical adenomatous hyperplasia | 4 | 25.0 |
| Subpleural fibrosis | 3 | 18.8 |
| Respiratory bronchiolitis with fibrosis and lymphocytic infiltration | 1 | 6.3 |
| Heavy lymphoplasma cell infiltration | 1 | 6.3 |
| Pulmonary lymphomatoid granulomatosis | 1 | 6.3 |
| Anthracofibrotic nodule with reactive pneumocytes | 1 | 6.3 |
Hospital stays, waiting times, and costs for patients undergoing surgical resection with and without tissue diagnosis
| Without tissue diagnosis | With tissue diagnosis | p-value | |
|---|---|---|---|
| (n =305) a | (n =26) | ||
| Days of hospitalization (days) | 6.8 ± 6.1 | 9.8 ± 4.3 | 0.015 |
| The time interval before surgery (days) | 2.5 ± 2.9 | 8.8 ± 8.5 | 0.001 |
| Total costs (US dollars) | 9271 ± 4430 | 11817 ± 2479 | 0.004 |
Unless otherwise specified, data are expressed as mean values ± standard deviations.
aData were evaluated for 305 operations in 300 patients, which included 330 nGGOs. Five patients had surgical resection twice for different nGGOs.